Cited by 581Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 215 of the 216 references it cites were found in a registry or an index.

Amyloid-β-independent regulators of tau pathology in Alzheimer disease

Open access

van der Kant, Rik, Goldstein, Lawrence S. B., Ossenkoppele, Rik·2020·Nature reviews. Neuroscience

DOI 10.1038/s41583-019-0240-3

Open this paper in CoChat — free account

Abstract

The global epidemic of Alzheimer disease (AD) is worsening, and no approved treatment can revert or arrest progression of this disease. AD pathology is characterized by the accumulation of amyloid-β (Aβ) plaques and tau neurofibrillary tangles in the brain. Genetic data, as well as autopsy and neuroimaging studies in patients with AD, indicate that Aβ plaque deposition precedes cortical tau pathology. Because Aβ accumulation has been considered the initial insult that drives both the accumulation of tau pathology and tau-mediated neurodegeneration in AD, the development of AD therapeutics has focused mostly on removing Aβ from the brain. However, striking preclinical evidence from AD mouse models and patient-derived human induced pluripotent stem cell models indicates that tau pathology can progress independently of Aβ accumulation and arises downstream of genetic risk factors for AD and aberrant metabolic pathways. This Review outlines novel insights from preclinical research that implicate apolipoprotein E, the endocytic system, cholesterol metabolism and microglial activation as Aβ-independent regulators of tau pathology. These factors are discussed in the context of emerging findings from clinical pathology, functional neuroimaging and other approaches in humans. Finally, we discuss the implications of these new insights for current Aβ-targeted strategies and highlight the emergence of novel therapeutic strategies that target processes upstream of both Aβ and tau.

Integrity signals

Registry

Crossref · 10.1038/s41583-019-0240-3

Cites

215 of 215 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases
Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979

Show all 216 references

Research works printed but not linked: 7

Kemp, A. Update on phase III clinical trials of lanabecestat for Alzheimer’s disease. AstraZeneca https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-phase-iii-clinical-trials-of-lanabecestat-for-alzheimers-disease-12062018.html (2018).
Jansen, W. J. et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313, 1924–1938 (2015). This large meta-analysis provides prevalence estimates of Aβ positivity in cognitively normal persons and patients with MCI. · DOI · Paper page
Cho, H. et al. Progressive tau accumulation in Alzheimer’s disease: two-year follow-up study. J. Nucl. Med. 60, 1611–1621 (2019). · DOI · Paper page
Hutter-Paier, B. et al. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer’s disease. Neuron 44, 227–238 (2004). This study shows that cholesteryl esters can drive accumulation of Aβ pathology in AD mice and that ACAT inhibitors have potential utility in the treatment of AD. · DOI · Paper page
Mecozzi, V. J. et al. Pharmacological chaperones stabilize retromer to limit APP processing. Nat. Chem. Biol. 10, 443–449 (2014). This revolutionary biochemical study uses in silico screening to discover a small molecule that is capable of stabilizing the retromer complex. · DOI · Paper page
Shi, Y. et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523–527 (2017). This elegant mouse study shows that the ApoE*4 genotype affects tau pathology in the absence of Aβ pathology. · DOI · Paper page
Santacruz, K. et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476–481 (2005). This is the first study to show that reducing tau expression in tau transgenic mice can rescue neuronal loss and behavioural deficits, even when extensive neurofibrillary tangles are already present. · DOI · Paper page

Sorted by citations

Items 301–400 of 581

Arginine Reduces Glycation in γ2 Subunit of AMPK and Pathologies in Alzheimer’s Disease Model Mice
Zhu, R., Lei, Y., Shi, F.-X., Tian, Q., & Zhou, X. (2022) · Cells · doi:10.3390/cells11213520 · Cited by 11
Nutritional assessment models for Alzheimer's disease: Advances and perspectives
Wen, Y., Zhang, L., Li, N., Tong, A., & Zhao, C. (2023) · Food Frontiers · doi:10.1002/fft2.216 · Cited by 11
Functional and structural connectivity in the Papez circuit in different stages of Alzheimer’s disease
Harı, E., Kizilates-Evin, G., Kurt, E., Bayram, A., Ulaşoğlu-Yıldız, Ç., Gurvit, H. I., & Demıralp, T. (2023) · Clinical Neurophysiology · doi:10.1016/j.clinph.2023.06.008 · Cited by 14
Connecting GSK-3β Inhibitory Activity with IKK-β or ROCK-1 Inhibition to Target Tau Aggregation and Neuroinflammation in Alzheimer’s Disease—Discovery, In Vitro and In Cellulo Activity of Thiazole-Based Inhibitors
Góral, I., Wichur, T., Sługocka, E., Godyń, J., Szałaj, N., Zaręba, P., Głuch‐Lutwin, M., Mordyl, B., Panek, D., & Więckowska, A. (2024) · Molecules · doi:10.3390/molecules29112616 · Cited by 12
Sequence of Molecular Events in the Development of Alzheimer’s Disease: Cascade Interactions from Beta-Amyloid to Other Involved Proteins
Bagheri, S., Saboury, A. A., & Saso, L. (2024) · Cells · doi:10.3390/cells13151293 · Cited by 12
Differential neuropsychiatric associations of plasma biomarkers in older adults with major depression and subjective cognitive decline
Wei, Y., Kung, Y., Lin, C., Yeh, C., Chen, P., Huang, W., Shyu, Y., Lin, C., & Chen, C. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03049-w · Cited by 11
Longitudinal relationships between Aβ and tau to executive function and memory in cognitively normal older adults
Chen, X., Juarez, A., Mason, S. M., Kobayashi, S., Baker, S. L., Harrison, T. M., Landau, S. M., & Jagust, W. J. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.10.004 · Cited by 11
Dihydroartemisinin Ameliorates Decreased Neuroplasticity-Associated Proteins and Excessive Neuronal Apoptosis in APP/PS1 Mice
Zhao, Y., Long, Z., Liu, Y., Luo, M., Qiu, Y. L., Idris, N. F. B., Song, A., Wang, K., & He, G. (2021) · Current Alzheimer Research · doi:10.2174/1567205017666201215124746 · Cited by 11
REMOVED: Alzheimer's disease neuropathology is exacerbated following traumatic brain injury. Neuroprotection by co-administration of nanowired mesenchymal stem cells and cerebrolysin with monoclonal antibodies to amyloid beta peptide
Sharma, H. S., Muresanu, D. F., Nozari, A., Lafuente, J. V., Buzoianu, A. D., Sahib, S., Tian, Z. R., Bryukhovetskiy, I., Manzhulo, I., Menon, P. K., et al. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2021.04.008 · Cited by 11
Amyloid-Driven Tau Accumulation on Mitochondria Potentially Leads to Cognitive Deterioration in Alzheimer’s Disease
Cuadrado‐Tejedor, M., Pérez-González, M., Alfaro‐Ruiz, R., Badesso, S., Sucunza, D., Espelosin, M., Ursúa, S., Lachén‐Montes, M., Fernández‐Irigoyen, J., Santamaría, E., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111950 · Cited by 11
Hypoxic Preconditioning Averts Sporadic Alzheimer's Disease-Like Phenotype in Rats: A Focus on Mitochondria
Correia, S. C., Alves, M. G., Oliveira, P. F., Casadesús, G., LaManna, J. C., Perry, G. L., & Moreira, P. I. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.8007 · Cited by 11
The relationships between neuroglial alterations and neuronal changes in Alzheimer’s disease, and the related controversies I: Gliopathogenesis and glioprotection
Toledano‐Díaz, A., Álvarez, M., & Tolédano, A. (2022) · Journal of Central Nervous System Disease · doi:10.1177/11795735221128703 · Cited by 11
Comparative binding analysis of WGX50 and Alpha-M with APP family proteins APLP1 and APLP2 using structural-dynamics and free energy calculation approaches
Ali, A., Masood, A., Khan, A. A., Zhu, F.-Y., Cheema, M. A. R., Samad, A., Wadood, A., Khan, A., Yu, Q., Heng, W., et al. (2023) · Physical Chemistry Chemical Physics · doi:10.1039/d2cp06083c · Cited by 11
Regional cerebral tau predicts decline in everyday functioning across the Alzheimer’s disease spectrum
Dubbelman, M. A., Mimmack, K. J., Sprague, E. H., Amariglio, R. E., Vannini, P., Marshall, G. A., & Initiative, A. D. N. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01267-w · Cited by 11
The Tetramethylpyrazine Analogue T-006 Alleviates Cognitive Deficits by Inhibition of Tau Expression and Phosphorylation in Transgenic Mice Modeling Alzheimer’s Disease
Zhang, G., Wu, J., Huang, C., Cheng, J., Su, Z., Zhu, Z., Yang, X., Guo, B., Wu, L., Zhang, Z., et al. (2021) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01762-x · Cited by 11
Mechanics of Lymphatic Pumping and Lymphatic FunctionPreprint
Razavi, M. S., Munn, L. L., & Padera, T. P. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041171 · Cited by 11
Lost in space(s): Multimodal neuroimaging of disorientation along the Alzheimer's disease continuum
Peters‐Founshtein, G., Gazit, L., Naveh, T., Domachevsky, L., Korczyn, A. D., Bernstine, H., Shaharabani‐Gargir, L., Groshar, D., Marshall, G. A., & Arzy, S. (2024) · Human Brain Mapping · doi:10.1002/hbm.26623 · Cited by 10
Liver-X receptor β-selective agonist CE9A215 regulates Alzheimer’s disease-associated pathology in a 3xTg-AD mouse model
Ban, S. Y., Nam, Y., Do, T. T., Kim, B., Shin, S. J., Nguyen, M. T. T., Kim, J., Moon, M., & Park, J. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117895 · Cited by 11
The Emergence of Model Systems to Investigate the Link Between Traumatic Brain Injury and Alzheimer’s Disease
Srinivasan, G. R., & Brafman, D. A. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.813544 · Cited by 10
Altered DNA methylome profiles of blood leukocytes in Chinese patients with mild cognitive impairment and Alzheimer’s disease
Wu, S., Yang, F., Shan, C., Wang, B., Wang, W., Li, H., Yu, L., He, L., Li, X., Sun, L., et al. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1175864 · Cited by 10
Novel Development and Prospects in Pathogenesis, Diagnosis, and Therapy of Alzheimer’s Disease
Teng, Z. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230130 · Cited by 10
The neurogenic niche in Alzheimer’s disease
Wander, C. M., & Song, J. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.136109 · Cited by 9
Understanding monocyte-driven neuroinflammation in Alzheimer’s disease using human cortical organoid microphysiological systems
Tian, C., Ao, Z., Cerneckis, J., Cai, H., Chen, L., Niu, H., Takayama, K., Kim, J., Shi, Y., Gu, M., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu2708 · Cited by 9
“We specifically chose to use cortical organoids because cortical neuropathology is evident in AD and contributes to cognitive decline ( 71 ).”
Neuronal Stem Cells from Late-Onset Alzheimer Patients Show Altered Regulation of Sirtuin 1 Depending on Apolipoprotein E Indicating Disturbed Stem Cell Plasticity
Jung, M., Jung, J., Pfeifer, J., Hartmann, C., Ehrhardt, T., Abid, C. L., Kintzel, J., Puls, A., Santos, A. N., Hollemann, T., et al. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03633-z · Cited by 9
Repetitive transcranial magnetic stimulation for Alzheimer’s disease: an overview of systematic reviews and meta-analysis
Xue, H., Li, Y., Xiao, Y.-S., Fan, W.-H., & He, H. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1383278 · Cited by 12
Decoding the Role of Neurotrophins in Glycogen Synthase Kinase 3-Beta Regulation in Alzheimer’s Disease
Rahmatkar, S. N., & Singh, D. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04776-x · Cited by 10
Higher Educational Attainment and Accelerated Tau Accumulation in Alzheimer Disease
Cai, Y. Q., Fang, L., Yang, J., Zhou, X. Y., Liu, L., Li, A., Sun, P., Lan, G., He, Z., Zhu, Y., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.1801 · Cited by 10
Puerarin as a multi-targeted modulator of lipid metabolism: molecular mechanisms, therapeutic potential and prospects for nutritional translation
Ou, S., Liang, Q., Leng, Y., Luo, T., Xu, X., Xie, H., Gao, H., Li, J., & Xie, C. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1598897 · Cited by 9
Hippocampal tau distribution in primary age‐related tauopathy: The Vantaa 85+ Study
Savola, S. E., Tuimala, J., Kivistö, V., Kero, M., Raunio, A., Kumar, D., Puttonen, H. A. J., Tynninen, O., Paetau, A. E., Polvikoski, T. M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70613 · Cited by 10
Clinical Utility of the Pathogenesis-Related Proteins in Alzheimer’s Disease
Zhou, B., & Fukushima, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228661 · Cited by 10
A Combined Chronic Low-Dose Soluble Epoxide Hydrolase and Acetylcholinesterase Pharmacological Inhibition Promotes Memory Reinstatement in Alzheimer’s Disease Mice Models
Jarné‐Ferrer, J., Griñán‐Ferré, C., Bellver‐Sanchís, A., Vázquez, S., Muñoz‐Torrero, D., & Pallàs, M. (2022) · Pharmaceuticals · doi:10.3390/ph15080908 · Cited by 9
DLK-MAPK Signaling Coupled with DNA Damage Promotes Intrinsic Neurotoxicity Associated with Non-Mutated Tau
Li, S., Roy, E. R., Wang, Y., Watkins, T. A., & Cao, W. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03720-1 · Cited by 14
The role of ATP‐binding cassette transporter G1 (ABCG1) in Alzheimer's disease: A review of the mechanisms
Yazdi, M. K., Alavi, M. S., & Roohbakhsh, A. (2024) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13981 · Cited by 11
Recent advances in nanoenzymes for Alzheimer's disease treatment
Bi, X., Cao, N., & He, J. (2024) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2024.114139 · Cited by 10
Importance of cerebrospinal fluid storage conditions for the Alzheimer’s disease diagnostics on an automated platform
Ferrer, R., Zhu, N., Arranz, J., Porcel, I., Bounasri, S. E., Sànchez, O., Torres, S., Julve, J., Lleó, A., Blanco‐Vaca, F., et al. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-0134 · Cited by 9
Associations Between Free and Cued Selective Reminding Test and Cerebrospinal Fluid Biomarkers in Amnestic Mild Cognitive Impairment
Giuffrè, G. M., Quaranta, D., Citro, S., Morganti, T. G., Martellacci, N., Vita, M. G., Rossini, P. M., Calabresi, P., & Marra, C. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240150 · Cited by 8
Unveiling the Interplay: Neurovascular Coupling, Astrocytes and G Protein-Coupled Receptors in Alzheimer’s Disease
Al-Jaf, S., Soliman, A. Y., EL‐Yazbi, A. F., & Abd‐Elrahman, K. S. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00614 · Cited by 8
Identification of a novel pyrrolo[2,3- b ]pyridine compound as a potent glycogen synthase kinase 3β inhibitor for treating Alzheimer’s disease
Xun, Q., Zhang, J., Feng, L., Ma, Y., Li, Y., & Shi, X. (2025) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2025.2466846 · Cited by 8
Polarity-responsive fluorescence lifetime probe for in vivo imaging of Aβ plaque dynamics: Unveiling PBM-induced Aβ polarity reversal
Huang, Z., Wang, Y., Lin, F., Luo, Z., Xu, H., Alifu, N., Li, J., Weng, X., Sun, Y., Song, J., et al. (2025) · Matter · doi:10.1016/j.matt.2025.102102 · Cited by 9
Distinct factors drive the progression of tau pathology in Alzheimer’s disease
Luo, Y., Yu, H., & Ye, K. (2025) · Fundamental Research · doi:10.1016/j.fmre.2025.04.001 · Cited by 9
Age-dependent elevation of Nr4a1 attenuates PI3K/AKT/GSK3β pathway and mediates tau hyperphosphorylation and cognitive impairments
Ling, L., Guo, Q., Cheng, Y., Gui, Y., Li, W., Zhao, Y., Xu, Z., Luo, Y., Wu, G., Wang, J., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.06.033 · Cited by 10
Brain organoids: a new paradigm for studying human neuropsychiatric disorders
Sun, Y. E., & Pan, W. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1699814 · Cited by 10
Altered Blood and Brain Expression of Inflammation and Redox Genes in Alzheimer’s Disease, Common to APPV717I × TAUP301L Mice and Patients
Cucoș, C. A., Milanesi, E., Dobre, M., Musat, I. A., Manda, G., & Cuadrado, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105799 · Cited by 8
Lipid-Lowering Drug Gemfibrozil Protects Mice from Tay-Sachs Disease via Peroxisome Proliferator-Activated Receptor α
Raha, S., Dutta, D., Paidi, R. K., & Pahan, K. (2023) · Cells · doi:10.3390/cells12242791 · Cited by 8
Hydrodynamic Control of Alzheimer Aβ Fibrillation with Glucosaminic Acid Containing Click-Cyclized β-Bodies
Zhang, Y., Borch, L. A., Fischer, N. H., & Meldal, M. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c12118 · Cited by 8
Bridging Reduced Grip Strength and Altered Executive Function: Specific Brain White Matter Structural Changes in Patients with Alzheimer’s Disease
Liu, S., Ma, X., Yu, S., Weng, X., Li, M., Zhu, J., Liu, C.-F., & Hu, H. (2024) · Clinical Interventions in Aging · doi:10.2147/cia.s438782 · Cited by 9
Neuronal glutathione depletion elevates the Aβ42/Aβ40 ratio and tau aggregation in Alzheimer's disease mice
Hashim, K. N. B., Matsuba, Y., Takahashi, M., Kamano, N., Tooyama, I., Saido, T. C., & Hashimoto, S. (2024) · FEBS Letters · doi:10.1002/1873-3468.14895 · Cited by 9
Involvement of CRMP2 Phosphorylation in Amyloid Beta-induced Tau Phosphorylation of Hippocampal Neurons in Alzheimer’s Disease Mouse Model
Noguchi, D., Watamura, N., Nikkuni, M., Saido, T. C., Goshima, Y., & Ohshima, T. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04721-y · Cited by 9
Thiophene‐π‐Cyanoacetamides Show Intense and Tau‐selective Turn‐on Fluorescence in the Near‐Infrared Region
Oh, Y., Lee, T., Kim, M. K., & Chong, Y. (2021) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.12361 · Cited by 8
Findings of 18F‐PI ‐2620 tau PET imaging in patients with Alzheimer’s disease and healthy controls in relation to the plasma P‐tau181 levels in a Japanese sample
Bun, S., Moriguchi, S., Tezuka, T., Sato, Y., Takahata, K., Seki, M., Nakajima, S., Yamamoto, Y., Sano, Y., Suzuki, N., et al. (2022) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12281 · Cited by 8
Associations of Stages of Objective Memory Impairment with Cerebrospinal Fluid and Neuroimaging Biomarkers of Alzheimer's Disease
Petersen, K. K., Ezzati, A., Lipton, R. B., Gordon, B. A., Hassenstab, J. J., Morris, J. C., & Grober, E. H. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.98 · Cited by 8
A Multiform Heterogeneity Framework for Alzheimer’s Disease Based on Multimodal Neuroimaging
Zhao, K., Chen, P., Wang, D., Zhou, R., Ma, G., & Liu, Y. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.12.009 · Cited by 6
Navigating neurodegeneration: challenges, pathophysiology, biomarkers, and the promise of nanocrystals-based nanotherapeutics
Kaur, G., Dewangan, J. P., Kumari, A. R., & Shukla, R. (2025) · Journal of Microencapsulation · doi:10.1080/02652048.2025.2507637 · Cited by 7
The intrinsic connectivity between the default mode and dorsal attention networks is an independent fMRI biomarker of Alzheimer's disease pathology burden
Lombardo, D., & Beckmann, C. F. (2025) · NeuroImage · doi:10.1016/j.neuroimage.2025.121509 · Cited by 7
Targeting Alzheimer's pathophysiology with carbon dots: from mechanisms to therapy
Tripathi, S., Singh, R., Jaiswal, S., Sethi, M., Rana, R., Mishra, K., & Chourasia, M. K. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb02134k · Cited by 7
Rethinking early Alzheimer’s disease: An impaired internal model updating disorder?
Antonioni, A. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106790 · Cited by 8
Lipidomics and proteomics: An integrative approach for early diagnosis of dementia and Alzheimer’s disease
Tiwari, V., & Shukla, S. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1057068 · Cited by 9
Palladium nanoballs coupled with smartphone-thermal reader for photothermal lateral flow immunoassay of Aβ 1-40
Cai, X., Luo, Y., & Song, Y. (2024) · Journal of Materials Chemistry B · doi:10.1039/d3tb02641h · Cited by 7
Distinct biological property of tau in tau‐first cognitive proteinopathy: Evidence by longitudinal clinical neuroimaging profiles and compared with late‐onset Alzheimer disease
Chang, H., Huang, C., Huang, S., Hsu, S., Lin, K., Ho, T., Wu, H., & Chang, C. (2024) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13680 · Cited by 7
Molecular imaging for neurological diseases
Zuo, C., Ge, J., Wang, J., Watanabe, Y., & Tian, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95223-1.00003-5 · Cited by 7
Unveiling the Therapeutic Potential of Kelulut (Stingless Bee) Honey in Alzheimer’s Disease: Findings from a Rat Model Study
Shaikh, A., Ahmad, F., Teoh, S. L., Kumar, J., & Yahaya, M. F. (2024) · Antioxidants · doi:10.3390/antiox13080926 · Cited by 10
Luteolin Ameliorates Methamphetamine-Induced Podocyte Pathology by Inhibiting Tau Phosphorylation in Mice
Ding, J., Wang, Y., Wang, Z., Hu, S., Zhu, L., Le, C., Huang, J. A., Xu, X., Huang, J., & Qiu, P. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/5909926 · Cited by 7
Buyang Huanwu Decoction Modulates the Gut Microbiota–C/EBPβ/ AEP Axis to Ameliorate Cognitive Impairment in Alzheimer's Disease Mice
Liang, J., Dong, X., Yang, J., Hu, N., Luo, X., Cong, S., Chen, J., Zhao, W., & Liu, B. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70480 · Cited by 7
PANoptosis: Potential Therapeutic Prospects in Alzheimer's Disease
Guo, Z., & Wan, Y. (2025) · European Journal of Neuroscience · doi:10.1111/ejn.70231 · Cited by 9
From clinical phenotype to proteinopathy: molecular neuroimaging in neurodegenerative dementias
Studart‐Neto, A., & Coutinho, A. M. (2022) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x-anp-2022-s138 · Cited by 6
Rose Bengal inhibits β-amyloid oligomers-induced tau hyperphosphorylation via acting on Akt and CDK5 kinases
Mou, C., Xie, Y., Wei, J., Wang, Q.-Y., Le, J., Bao, Y., Zhang, P., Mao, Y., Huang, X.-H., Pan, H., et al. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06232-3 · Cited by 7
Mechanism of action deconvolution of the small-molecule pathological tau aggregation inhibitor Anle138b
Hosseini-Gerami, L., Ficulle, E., Humphryes-Kirilov, N., Airey, D. C., Scherschel, J., Kananathan, S., Eastwood, B. J., Bose, S., Collier, D. A., Laing, E., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01182-0 · Cited by 6
Novel Phenylethanoid Glycosides Improve Hippocampal Synaptic Plasticity via the Cyclic Adenosine Monophosphate-CREB-Brain-Derived Neurotrophic Growth Factor Pathway in APP/PS1 Transgenic Mice
Ji, S., Wu, Y., Zhu, R., Guo, D., Jiang, Y., Huang, L., Ma, X., & Yu, L. (2023) · Gerontology · doi:10.1159/000531194 · Cited by 6
Novel hyperbranched rolling circle amplification-driven aptasensor for ultrasensitive and multiplex biomarkers detection of Alzheimer's disease
Zhong, J., Wang, Q., Li, Q., Cui, S., Chen, K., Gu, T., Li, S., & Bai, P. (2025) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2025.137816 · Cited by 6
Computational discovery of plant-derived flavonoids as potential amyloid-β fibril disaggregating agents for alzheimer’s disease
Rakesh, U. L., Kumar, G. A., Theivendren, P., Pavadai, P., Veerachamy, S., Palanisamy, P., Bandral, S. K., & Kunjiappan, S. (2025) · Brain Disorders · doi:10.1016/j.dscb.2025.100233 · Cited by 7
Roles of Ion Channels in Oligodendrocyte Precursor Cells: From Physiology to Pathology
Wang, J., Shen, Y., Liao, P. S., Yang, B., & Jiang, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157336 · Cited by 10
Down-regulation of cyclin D2 in amyloid β toxicity, inflammation, and Alzheimer’s disease
Czapski, G. A., Cieślik, M., Białopiotrowicz, E., Lukiw, W. J., & Strosznajder, J. B. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259740 · Cited by 6
Role of Oxysterols in the Activation of the NLRP3 Inflammasome as a Potential Pharmacological Approach in Alzheimer's Disease
Martins, G. L., Ferreira, C. N., Palotás, A., Rocha, N. P., & Reis, H. J. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220327215245 · Cited by 6
Interdependent Attribute Interference Fuzzy Neural Network-Based Alzheimer Disease Evaluation
Ahmed, S. T., Koti, M. S., Muthukumaran, V., Joseph, R. B., & Satheesh Kumar, S. (2022) · International Journal of Fuzzy System Applications · doi:10.4018/ijfsa.306275 · Cited by 6
Association of apolipoprotein E epsilon 4 and cognitive impairment in adults living with human immunodeficiency virus: a meta-analysis
Mu, T., Wei, J., Sun, J., Jin, J., Zhang, T., Wu, H., & Su, B. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002480 · Cited by 8
Clinical Management in Alzheimer’s Disease in the Era of Disease-Modifying Therapies
Guo, M. H., & Vaishnavi, S. (2023) · Current Treatment Options in Neurology · doi:10.1007/s11940-023-00750-x · Cited by 6
Significance of a positive tau PET scan with a negative amyloid PET scan
Robinson, C. G., Lee, J., Min, H.-K. P., Przybelski, S. A., Josephs, K. A., Jones, D. T., Graff‐Radford, J., Boeve, B. F., Knopman, D. S., Jack, C. R., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13608 · Cited by 8
Discovery of cinnamamide/ester triazole hybrids as potential treatment for Alzheimer’s disease
Tan, L.-J., Lei, W.-J., Liu, M., Cai, Z., Jiang, H., Liu, R., & Li, Z. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107584 · Cited by 6
Molecular dynamics of amyloid-β transport in Alzheimer's disease: Exploring therapeutic plasma exchange with albumin replacement – Current insights and future perspectives
Mondal, R., Deb, S., Shome, G., Sarkar, V., Lahiri, D., Datta, S. S., & Benito‐León, J. (2024) · Neurología · doi:10.1016/j.nrl.2023.11.005 · Cited by 6
A Systematic Review of Updated Mechanistic Insights Towards Alzheimer’s Disease
Mittal, A., Sharma, R., Sardana, S., Goyal, P. K., Piplani, M., & Pandey, A. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220510144127 · Cited by 6
Coupling of the spatial distributions between sMRI and PET reveals the progression of Alzheimer’s disease
Zhao, K., Lin, J., Dyrba, M., Wang, D., Che, T., Wu, H., Wang, J., Liu, Y., & Li, S. (2022) · Network Neuroscience · doi:10.1162/netn_a_00271 · Cited by 6
Plasma biomarker trajectories: Impact of AD genetic risk and clinical progression
Pettigrew, C. A., Soldan, A., Wang, J., Hohman, T. J., Dumitrescu, L. C., Albert, M., Blennow, K., Bittner, T., Moghekar, A., & The BIOCARD Study Team (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70081 · Cited by 5
The emerging role of cuproptosis in spinal cord injury
Xu, D., Hu, L., Zhou, J., Deng, X., Zhu, Y., & Liu, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1595852 · Cited by 5
iPSC-derived neural organoids in dementia research: Recent advances and future directions
Shima, S., Kondo, T., & Inoue, H. (2025) · Neuroscience Research · doi:10.1016/j.neures.2025.104980 · Cited by 6
Multi‐Target‐Directed Ligands ( MTDLs ) as Potential Therapeutic Candidates Targeting Multiple Pathogenic Factor of Alzheimer's Disease
Jung, J., Kim, Y., Cirunduzi, A. C., Yoon, S., Bang, S., & Yang, S. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.70919 · Cited by 5
Familial Alzheimer’s Disease Neurons Bearing Mutations in PSEN1 Display Increased Calcium Responses to AMPA as an Early Calcium Dysregulation Phenotype
Anastacio, H. T. D., Matosin, N., & Ooi, L. (2024) · Life · doi:10.3390/life14050625 · Cited by 6
Identifying the Role of Oligodendrocyte Genes in the Diagnosis of Alzheimer's Disease through Machine Learning and Bioinformatics Analysis
Chen, Y., Li, C., Yao, Y., & Yazhen, S. (2024) · Current Alzheimer Research · doi:10.2174/0115672050338777241028071955 · Cited by 6
The rise of probiotics as adjuvant therapeutics in Alzheimer’s disease
Noreña, C. P. Z., & Brandelli, A. (2025) · Discover Food · doi:10.1007/s44187-025-00523-2 · Cited by 6
Applications of single‐cell multi‐omics sequencing in deep understanding of brain diseases
Zhang, X., Lü, P., & Shen, X. (2022) · Clinical and Translational Discovery · doi:10.1002/ctd2.95 · Cited by 6
Exosomes derived from mesenchymal stem cells overexpressing miR-210 inhibits neuronal inflammation and contribute to neurite outgrowth through modulating microglia polarization
Xiong, Q.-H., Zhao, L., Wan, G., Hu, Y., & Li, X. (2023) · Open Medicine · doi:10.1515/med-2022-0618 · Cited by 6
Does a pickle a day keep Alzheimer's away? Fermented food in Alzheimer's disease: A review
Tyliszczak, M., Wiatrak, B., Danielewski, M., Szeląg, A., Kucharska, A. Z., & Sozański, T. (2023) · Experimental Gerontology · doi:10.1016/j.exger.2023.112332 · Cited by 6
Amyloid cross-sequence interaction between Aβ(1‐40) and αA(66–80) in relation to the pathogenesis of cataract
Schimansky, A., & Yadav, J. K. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.02.111 · Cited by 5
Ausscheiden aus der Währungsunion? -- Rechtliche Fragen
Seidel, M. (2007) · Europaische zeitschrift für wirtschatsrecht, EUZW · Cited by 5
NeuroProtect, a Candidate Formula From Traditional Chinese Medicine, Attenuates Amyloid-β and Restores Synaptic Structures in APP/PS1 Transgenic Mice
Tan, Y. L., Wang, X., Zhang, J., Zhang, H., Li, H., Peng, T., Chen, W., Wei, P., Liu, Z., He, F., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.850175 · Cited by 5
Next-generation Alzheimer's Therapeutics: Leveraging Deep Biology
Longo, F. M., & Massa, S. M. (2020) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2020.30 · Cited by 5
Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s diseasePreprint
Rubinski, A., Franzmeier, N., Dewenter, A., Luan, Y., Smith, R. A., Strandberg, O. T., Ossenkoppele, R., Dichgans, M., Hansson, O., Ewers, M., et al. (2022) · medRxiv · doi:10.1101/2022.03.02.22271746 · Cited by 5
Self-citation
Integrative mapping of spatial transcriptomic and amyloid pathology in Alzheimer’s disease at single-cell resolutionPreprint
Zhang, G., Xia, S., Zhang, N. K., Gao, F., Zloković, B. V., Zhang, L. I., Zhao, Z., & Tao, H. W. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.07.539389 · Cited by 5
Neurons accumulate disease-specific somatic genomic changes across tau pathologic states in Alzheimer’s diseasePreprint
Jin, B., Brown, K. S.-M., Smirnov, D. S., Naik, S. M., Kirkham, S. L., Hennessey, E. L., Dong, G., Mao, S., Wijethunga, S. P., Connors, T. R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.26.656152 · Cited by 6
Interactions of Extracts from Selected Plant Materials Supporting the Treatment of Alzheimer’s Disease with Free Radicals—EPR and UV-Vis Studies
Łomankiewicz, D., Pilawa, B., Chodurek, E., & Zdybel, M. (2025) · Pharmaceuticals · doi:10.3390/ph18091421 · Cited by 4
Molecular pathology and biomarker of progression in Alzheimer’s disease
Husain, M. (2022) · Brain · doi:10.1093/brain/awac209 · Cited by 4

Authors: van der Kant, R., Goldstein, L. S. B., & Ossenkoppele, R.
Affiliations: University of California San Diego (US)
Lund University (SE)
ORCID: van der Kant, Rik
Goldstein, Lawrence S. B.
Ossenkoppele, Rik
Venue: Nature reviews. Neuroscience
Publisher: Springer Science and Business Media LLC
Published: 2019-11-28
Volume: 21
Issue: 1
Pages: 21-35
ISSN: 1471-003X (ISSN-L)
1471-0048
DOI: 10.1038/s41583-019-0240-3
OpenAlex: W2989855650
Cited by: 580
References: 216
Citations by year: 2026: 57 · 2025: 89 · 2024: 93 · 2023: 89 · 2022: 95 · 2021: 95 · 2020: 61
FWCI: 7.39
Type: journal article
Language: en
Open access: green
research.vu.nl
Licence: other-oa
www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature reviews. Neuroscience (publishedVersion)
PubMed (publishedVersion)
VU Research Portal (publishedVersion, other-oa)
Lund University Publications (Lund University) (submittedVersion)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion)
Funders: National Institute on Aging (RF1AG048083)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: Alzheimer's disease, tau pathology, amyloid-beta, apolipoprotein E, cholesterol metabolism, microglial activation, induced pluripotent stem cell models, mouse model
MeSH terms: Alzheimer Disease, Animals, Apolipoproteins E, Cholesterol, Endocytosis, Humans, Amyloid beta-Peptides, tau Proteins, Microglia, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Amyloid-β-independent regulators of tau pathology in Alzheimer disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks